A Phase 2b clinical trial of EVO756 for Migraine
Latest Information Update: 20 May 2026
At a glance
- Drugs EVO 756 (Primary)
- Indications Migraine
- Focus Therapeutic Use
Most Recent Events
- 07 May 2026 According to a Evommune media release, company plans to initiate a Phase 2b dose-ranging clinical trial in migraine prophylaxis in mid-2026. Top-line data from the trial are anticipated in 2027.
- 15 Apr 2026 New trial record
- 06 Apr 2026 According to Evommune media release, the trial is expected to initiate in 3Q26.